CSL BEHRING LLC for CSL BEHRING LLC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Education efforts surrounding hemophilia B and a new gene therapy treatment that CSL Behring submitted to FDA, which has been licensed. Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
| MARY LACEY REUTHER | — |
Immigration IMM
Customs and Border Protection policy regarding B1/B2 visa holder eligibility to cross the US border to donate plasma.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
| MARY LACEY REUTHER | — |
Taxation/Internal Revenue Code TAX
Sought to include language that would delay the requirement to amortize Research & Development expenses over 5 years instead of obtaining an immediate deduction from taxable income.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.